News | February 16, 2024
Glenmark Pharma posts Q3 FY24 net loss of Rs. 331 Cr
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
The CDCCs are strategically positioned in regions identified as high-impact areas
The new tests can support clinical decision making when prescribing direct oral anticoagulants for stroke prevention
Launches collaborative centre for translational research in head and neck cancer
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
_256_384.png){kind=logo}
4 FDA clearances & 61 EU MDR CE tags achieved for AI in 18 months
Exblifeb demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
Subscribe To Our Newsletter & Stay Updated
